24 GLP Toxicology CROs

What is GLP Toxicology and when do you need it?

GLP Toxicology is the set of definitive animal safety studies you run to prove it is reasonably safe to dose your molecule in a human for the first time. The studies are conducted under Good Laboratory Practice (21 CFR Part 58 in the US, OECD GLP elsewhere), which is the regulatory quality system that makes the data usable for human risk assessment. The core of it is repeat-dose toxicity testing, usually in two species (one rodent such as rat, one non-rodent such as dog, minipig, or non-human primate), dosed for a duration that supports the length of the clinical trial you want to run.

You need this work in the IND-enabling stage, the run-up to filing your Investigational New Drug application. It comes after the exploratory, non-GLP work of discovery and early preclinical (dose-range-finding, MTD reads, early ADME) and before first-in-human dosing. The timing is driven by ICH M3(R2): the duration and design of your pivotal tox has to match the Phase 1 you are planning, so a 14-day repeat-dose Phase 1 needs different tox support than a single-ascending-dose study. Sponsors settle the design questions at a pre-IND meeting with the FDA, then book GLP capacity, because slot availability, not the science, is usually what sets the calendar.

The output a buyer cares about is concrete: a defined No-Observed-Adverse-Effect-Level (NOAEL), identified target organs of toxicity, reversibility data, toxicokinetic exposure that links animal doses to plasma concentrations, and a final GLP-compliant report a reviewer can read without flagging gaps. That package is what justifies your Phase 1 starting dose and dose-escalation plan. Almost no biotech owns a GLP toxicology facility, so this is one of the most heavily outsourced workstreams in all of drug development, which is exactly why it is worth comparing several qualified CROs rather than defaulting to the first quote.

What does a GLP Toxicology CRO actually do?

A GLP toxicology CRO runs the in-life safety studies and produces the regulatory-grade reports that go into Module 4 of your IND. In practice the engagement runs in phases: protocol design against ICH and FDA guidance, a non-GLP dose-range-finding study to set the doses, the pivotal GLP repeat-dose study with a named study director who owns the GLP record, the in-life dosing and observations, then clinical pathology, histopathology, and a draft and final report. The study director and the quality assurance unit are the two roles that make a study GLP rather than just well-run, so confirm both are real and in writing.

The technical scope under this category typically includes single-dose and repeat-dose general toxicology in two species, the toxicokinetic (TK) sampling built into those studies, clinical and anatomic pathology (hematology, clinical chemistry, gross necropsy, and histopathology by a board-certified pathologist), and the determination of NOAEL, target organs, and reversibility through a recovery cohort. The pivotal repeat-dose study is almost always the critical path of the whole IND-enabling program, and the non-rodent study usually costs and schedules harder than the rodent one.

It helps to know what sits next to this category rather than inside it. Safety pharmacology (the cardiovascular, CNS, and respiratory core battery plus the hERG assay), genetic toxicology (Ames, in vitro and in vivo micronucleus), and reproductive and developmental toxicology (DART) are separate IND-enabling services, though many full-service tox CROs run them together and a good vendor will run them in parallel with the pivotal tox so the timeline does not stack end to end. Toxicokinetics travels inside the GLP tox study and depends on a validated bioanalytical method, so confirm that method exists before the in-life phase starts.

How to choose a GLP Toxicology CRO?

For GLP tox, regulatory credibility outweighs almost everything else, so weight it heaviest and score two or three candidates against the same written scope rather than collecting quotes that measure different things. The cheapest bid rarely wins here: a study run non-GLP that a reviewer later expects in GLP, or a clinical hold from a thin package, costs far more than the savings. Match the vendor to your modality first, because a lab that is excellent at small-molecule tox can be a beginner at a non-human-primate biologic study or a gene-therapy biodistribution program, and the species selection and endpoints change completely across modalities.

• Quality and GxP status: confirm GLP compliance (21 CFR Part 58 or OECD GLP) for every pivotal study, ask for recent FDA and other regulatory inspection history, and check that the quality assurance unit and study director model are genuinely in place.
• Capacity and lead time: pin down real GLP slot availability and a milestone timeline (protocol, dose-range-finding, in-life, pathology, draft report, final report). Slot availability is the binding constraint more often than the science, so book pivotal capacity early.
• Modality and indication fit: ask how many comparable programs the team has finished in your modality (small molecule, monoclonal antibody, ADC, oligonucleotide, peptide, cell or gene therapy) and how many cleared a regulatory review, since species choice and immunogenicity needs differ sharply.
• Region and regulatory track record: confirm the vendor's data has supported submissions to the agencies you plan to file with (FDA, EMA, PMDA, NMPA) and that their reports are written to ICH M3(R2) and the relevant guidance.
• Data quality and reporting: check that toxicokinetic and bioanalytical methods are validated to the standard your submission needs, that pathology is read by a board-certified pathologist, and that you will receive an audit-ready report, not just raw tables.
• IP and confidentiality: settle who owns the data and study records, how the final report and raw data are transferred to you, and how the vendor handles a confidential program you may not want disclosed before you sign.